The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Official Title: P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer
Study ID: NCT04443348
Brief Summary: This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN only) * Capecitabine (optional, and in TN only)
Detailed Description: The main purpose of this study is to find out what is the best dose of preoperative RT when combined with pembrolizumab and chemotherapy. The study will assess if combining the RT with the immunotherapy agent, pembrolizumab, will increase the ability of the immune system to destroy cancer cells. The research study procedures include: screening for eligibility and study treatment, including evaluations and follow-up visits. The study aims to assess the effectiveness of pembrolizumab (study drug) with or without RT directed to the breast tumor. Participants will then undergo neoadjuvant chemotherapy with pembrolizumab, followed by treatment that can consist of one or more of the following: * Pembrolizumab (optional, per MD discretion) * Standard of Care Treatment * Breast surgery (lumpectomy or mastectomy) and axillary surgery * Adjuvant radiation to the entire breast or chest wall, plus or minus the lymph nodes after surgery * Adjuvant chemotherapy (optional Capecitabine for TNBC patients) * Hormone therapy Participants will be randomized to 1 of 3 groups. Neither the participant not the research doctor will choose the group that the participant is assigned to. However, the participant will be notified of the group prior to the start of study treatment. Participants will receive study treatment for up to 13 months. Participants will be followed for 2 years after the end of the study treatment. It is expected that a total of 120 people will be participating in total. This research study is a randomized, phase II study. The U.S. Food and Drug Administration (FDA) has not approved pembrolizumab for your specific disease, but it has been approved for other uses. The U.S. Food and Drug Administration (FDA) has approved the chemotherapies being used in this study (Paclitaxel, Doxorubicin, Cyclophosphamide, Carboplatin, Capecitabine).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Sibley Memorial Hospital, Washington, District of Columbia, United States
Johns Hopkins, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Montefiore Medical Center, Bronx, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
Name: Laura M Spring, MD
Affiliation: Massachusetts General Hospital
Role: PRINCIPAL_INVESTIGATOR